Kronos Bio ($KRON) Misleading Merger Proxy and Insider Enrichment Case

The plaintiff has voluntarily dismissed the case, ending the lawsuit.

N.D. California

Court

3:25-cv-04322

Case number

05/01/2025

Class period Start

07/21/2025

Lead Plaintiff motion deadline

$KRON investors filed a claim against Kronos Bio for misleading disclosures tied to its merger with Concentra and failing to share key financial information.
The case challenges the fairness of the $0.57-per-share tender offer and alleges that executives prioritized personal payouts over shareholder value.
$KRON investors can join this case to be notified about potential recovery.
Case Details:

On May 1, 2025, Kronos Bio announced it had agreed to be acquired by Concentra Biosciences for $0.57 per share in cash, plus a non-tradeable contingent value right (CVR) tied to the sale of its remaining drug candidates. Kronos filed a recommendation statement urging shareholders to tender their shares.

But the proxy lacked critical information. It did not include the financial projections Kronos shared with other bidders during the sales process, nor did it disclose how different confidentiality agreements may have influenced who could bid. The company also omitted details about potential post-merger employment negotiations that may have swayed board members.

The proxy further failed to fully explain the valuation assumptions behind Leerink’s fairness opinion, including key inputs used to calculate dissolution values. Meanwhile, top executives and directors stood to gain millions in merger-related payouts and golden parachutes—compensation that public shareholders would not receive.

Based on these events, $KRON investors filed a claim against Kronos Bio and its board, accusing them of the following:
It misled shareholders by omitting critical financial projections and deal background from the merger proxy.
It failed to disclose insider conflicts, including potential job offers and disproportionate payouts.
Considering all the representations, investors believe the Kronos board prioritized personal gain over securing full value for shareholders.

Case Type

US Securities Class Action

Case Status

Voluntary Dismissed

Alleged Offence

Misleading Statements,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

05/01/2025

Filing date

05/20/2025

Lead Plaintiff Deadline

07/21/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.